Valvular & structural heart disease
Effect of Valve Type and Anesthesia Strategy for Transcatheter Aortic Valve Replacement (TAVR): 5-Year Results of the SOLVE-TAVI Trial
Authors' conclusion
Transfemoral TAVR using either SEV and BEV as well as CS and GA showed similar clinical outcomes at 5 years using a combined clinical endpoint.
Study context
- Population
- Intermediate- to high-risk patients with severe, symptomatic AS undergoing transfemoral TAVR
- Participants
- 447 participants
- Comparison
- Self-expanding valves (SEV) vs balloon-expandable valves (BEV), and conscious sedation (CS) vs general anesthesia (GA), for transfemoral TAVR
Methodological detailsmulticentre, 2 × 2 factorial, open-label, 5-year follow-up
- Multicentre
- 2 × 2 factorial
- Open-label
- 5-year follow-up
Primary result
As reported in the abstract
5 years
SEV vs BEV
Estimate (95% CI)P value
Hazard ratiovalve comparison combined endpoint
0.89(0.70–1.13)
P = 0.34CS vs GA
Estimate (95% CI)P value
Hazard ratioanesthesia comparison primary endpoint
0.80(0.62–1.04)
P = 0.09Further findings
| Outcome | SEV | BEV | CS | GA | HR (95% CI) | P value | |
|---|---|---|---|---|---|---|---|
| Stroke (valve comparison) · 5 yearsSEV vs BEV | 2.2% | 9.6% | — not stated in the abstract | — not stated in the abstract | 4.84 (1.65–14.18) | P = 0.002 | |
| All-cause mortality (anesthesia comparison) · 5 yearsCS vs GA | — not stated in the abstract | — not stated in the abstract | 41.5% | 54.3% | 0.70 (0.53–0.94) | P = 0.02 | |
| 0.050.21520Hazard ratio (log scale) |
— not stated in the abstract
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effect of Valve Type and Anesthesia Strategy for TAVR: 5-Year Results of the SOLVE-TAVI Trial. J Am Coll Cardiol. Published 6 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →